The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters’ Over-Allotment Option
Jan 14, 2025•over 1 year ago
Contract Type
partnership
JilinManufacturingBiotechnology
Description
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) announced that the underwriter of its initial public offering (the 'Offering') have exercised in full their option to purchase an additional 225,000 ordinary shares at a public offering price of $4.00 per ordinary share to cover over-allotments. The gross proceeds of the Company's initial public offering, including the exercise of the over-allotment, totaled $6.9 million, before deducting underwriting discounts and other related expenses. Proceeds from the Offering will be used for acquiring vaccine production companies and conducting R&D projects.
Company Information
Company
Zhengye Biotechnology Holding Limited
Location
Jilin, China
About
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) is a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccine in China.
Predictive Intelligence
Strategic
ML-powered predictions for Zhengye Biotechnology Holding Limited's next move
JilinManufacturingBiotechnology